"If Brilacidin shows a reduction in mortality, wouldn't you agree that would be as good as raising someone from the dead?"
Fair point, if that reduction is so statistically significant as to be highly unlikely to be due to chance, which is a tall order in a 120 patient study.
But yes, I would agree, with those caveats.
"As for the other issues you mention, those are all logistical. We are in a pandemic, logistics are the least of our concerns."
The logistics of manufacture and supply of what we all hope (but some like me doubt) will be a widely-used life saving drug are rightly foremost among FDA's concerns- they should be ours too.
If you can't get access to this drug, then its efficacy is frankly irrelevant, and drug supply is actually quite a tricky matter.
Not least for a two person band like IPIX which has always focused more on selling stock than developing product.
News 
Market Data 
Discover 
AI
